Showing 6961-6970 of 9134 results for "".
- Water Baths As Effective As Bleach Baths for Eczemahttps://practicaldermatology.com/news/water-baths-as-effective-as-bleach-baths-for-eczema/2457967/Water baths are as good as bleach baths for treating eczema, and they are safer, finds a new Northwestern Medicine study. Bleach baths can cause stinging and burning of skin, and occasionally even trigger asthma flare-ups in patients. “I don’t know if it throws the bab
- Parent-supplied Photos May Allow Pediatric Derms to Make Virtual Diagnoseshttps://practicaldermatology.com/news/parent-supplied-photos-may-allow-pediatric-derms-to-make-virtual-diagnoses/2457968/Parent-supplied photos taken via smartphone cameras can allow pediatric dermatologists to make a diagnosis without an office visit in many cases, new research shows. This finding, which appear in JAMA Dermatology, suggest that direct-to-patient dermatology can accurate
- Sonoma Pharmaceuticals Launches Loyonhttps://practicaldermatology.com/news/sonoma-pharmaceuticals-launches-loyon/2457971/Sonoma Pharmaceuticals, Inc. has begun US commercialization of the company’s new Loyon® product. Under the supervision of a healthcare practitioner, Loyon is intended to manage and relieve the scaling, erythema, and itching associated with various types of dermatoses including seborrhea
- Research: Adequate Sleep May Speed Wound Healinghttps://practicaldermatology.com/news/research-adequate-sleep-may-speed-wound-healing/2457969/Getting more sleep may help wound healing, and a nutrition supplement can also add some benefit, according to a new study in the Journal of Applied Physiology. Physical and emotional str
- Ortho Dermatologics Announces Aspire Higher Scholarship Honoreeshttps://practicaldermatology.com/news/ortho-dermatologics-announces-aspire-higher-scholarship-honorees/2457972/Ortho Dermatologics announced the nine recipients of the Aspire Higher Scholarship program, which honors the achievements of applicants or current attendees of an accredited, nonprofit, two- or fou
- Calling all Innovators: J & J Launches Digital Beauty QuickFire Challengehttps://practicaldermatology.com/news/calling-all-innovators-j-j-launches-digital-beauty-quickfire-challenge/2457975/Johnson & Johnson Innovation LLC, in collaboration with Johnson & Johnson Consumer Inc., is launching the Digital Beauty QuickFire Challenge. The challenge will encourage start-up companies to create the most novel, future-forward digital
- Study: PsO, RA Patients Prescribed Similar Drugs, But PsO Patients Face Higher Liver Disease Riskhttps://practicaldermatology.com/news/study-pso-ra-patients-prescribed-similar-drugs-yet-pso-patients-face-higher-liver-disease-risk/2457987/Compared to controls, patients with psoriasis (PsO) are at higher risk for serious liver disease than patients with rheumatoid arthritis, reports a in the Journal of Investigative Dermatology from researchers a
- Gut Microbiome May Affect How Metastatic Melanoma Responds to Immunotherapyhttps://practicaldermatology.com/news/gut-microbiome-may-affect-how-metastatic-melanoma-responds-to-immunotherapy/2457986/The gut microbiome can influence how metastatic melanoma responds to immunotherapy, researchers from The University of Texas MD Anderson Cancer Center report in the journal
- Dermatomyositis Breakthrough? Drug reduces disease burden in patients with skin-predominant DMhttps://practicaldermatology.com/news/dermatomyositis-breakthrough-drug-reduces-disease-burden-in-patients-with-skin-predominant-dm/2457990/A new treatment for dermatomyositis (DM) may reduce the severity of the disease in patients whose DM was resistant to other therapies. As part of a randomized, double-blind study conducted at the Perelman School of Medicine at the University of Pennsyl
- Abbvie's Risankizumab Performs Well in Three Phase Three Psoriasis Studieshttps://practicaldermatology.com/news/abbvies-risankizumab-performs-well-in-three-phase-three-psoriasis-studies/2457991/Top-line results from three pivotal Phase 3 clinical trials show that risankizumab, an investigational interleukin-23 (IL-23) inhibitor,